BRIEF published on 11/22/2024 at 09:07, 1 day 2 hours ago Nabaltec AG Maintains Strong Performance with Positive EBIT Margin Outlook Financial Performance Investment Potential Nabaltec AG EBIT Growth Revenue Stability
PRESS RELEASE published on 11/22/2024 at 09:02, 1 day 2 hours ago Original-Research: Nabaltec AG (von NuWays AG): Buy Nabaltec AG research update by NuWays AG recommends buy with target price of EUR 25.00. Q3 sales steady at €49.8m, EBIT up by 30.4%. Strong balance sheet and growth potential Buy Recommendation NuWays AG Research Update Nabaltec AG EBIT Growth
BRIEF published on 11/21/2024 at 10:05, 2 days 1 hour ago Nabaltec AG Reports Stable Earnings in Q3 2024 Revenue Growth Market Position Nabaltec AG Functional Fillers Q3 2024 Earnings
PRESS RELEASE published on 11/21/2024 at 10:00, 2 days 1 hour ago Nabaltec AG continues solid earnings performance in third quarter of 2024 Nabaltec AG reports solid earnings performance with a 1.5% increase in consolidated revenues and 28.2% rise in EBIT for the third quarter of 2024 Revenues EBIT 2024 Nabaltec AG Earnings Performance
BRIEF published on 10/10/2024 at 09:06, 1 month 13 days ago Nabaltec Maintains Strong Growth Outlook Following Conference Insights Nabaltec ATH Demand White Powder Investment Boehmite Sales Share Valuation
PRESS RELEASE published on 10/10/2024 at 09:01, 1 month 13 days ago Original-Research: Nabaltec (von NuWays AG): Buy Analysis of Nabaltec by NuWays AG reveals strong demand for core product ATH, growing capacities for gap filler, emphasizing attractive growth potential with Q3 performance expected to be positive. Shares remain undervalued NuWays AG Growth Potential Undervalued Shares Nabaltec ATH
BRIEF published on 08/23/2024 at 09:11, 3 months ago Nabaltec AG Reports Strong Q2, Raises FY24 Guidance Cash Flow NuWays AG FY24 Guidance Nabaltec AG Q2 Earnings
PRESS RELEASE published on 08/23/2024 at 09:06, 3 months ago Original-Research: Nabaltec AG (von NuWays AG): BUY Nabaltec AG research by NuWays AG reveals strong Q2 figures, with sales up 11% yoy and EBIT jumping 79% yoy. FY24 guidance raised with sales growth and improved margins expected NuWays AG Research FY24 Guidance Nabaltec AG Q2 Figures
BRIEF published on 08/22/2024 at 10:09, 3 months 1 day ago Nabaltec AG Publishes Interim Report January to June 2024: Revenues on Track in Second Quarter Revenue Growth EBIT Margin Interim Report Nabaltec AG Functional Fillers
PRESS RELEASE published on 08/22/2024 at 10:04, 3 months 1 day ago Nabaltec AG publishes interim report January to June 2024: Revenues on track in second quarter Nabaltec AG's interim report Jan-Jun 2024 shows revenue growth of 2.2% to EUR 108.4M. EBIT reaches EUR 10.9M. Forecast for 2024: 2%-4% revenue growth and EBIT margin 8%-10% Revenue Growth EBIT Forecast Interim Report Nabaltec AG
Published on 11/22/2024 at 23:55, 11 hours 25 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 11 hours 50 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 12 hours 15 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 12 hours 50 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 17 hours 5 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 17 hours 26 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 18 hours 24 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 19 hours 20 minutes ago Proposed cancellation of admission to trading
Published on 11/21/2024 at 06:58, 2 days 4 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 16 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 17 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 17 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
